Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries

Current Medical Research and Opinion

Volumn 25, Issue 7, 2009, Pages 1793-1805

  Paradis, Pierre Emmanuel ^a   Latrémouille Viau, Dominick ^a   Moore, Yuliya ^a   Mishagina, Natalia ^a   Lafeuille, Marie Hélene ^a   Lefebvre, Patrick ^a   Gaudig, Maren ^b   Mei, Sheng Duh ^c  

^a GROUPE D ANALYSE   (Canada)

^b JANSSEN CILAG GMBH   (Germany)

^c ANALYSIS GROUP   (United States)

Author keywords

Antiepileptic drugs; Budget impact; Cost conversion; Generic substitution

Indexed keywords

GENERIC DRUG; TOPIRAMATE;

ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DRUG COST; DRUG USE; EPILEPSY; EUROPE; FEMALE; FRANCE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; ITALY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CANADA; CHILD; CHILD, PRESCHOOL; DRUGS, GENERIC; EUROPE; EUROPEAN UNION; FEMALE; FORECASTING; FRUCTOSE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 67650457573     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903044374     Document Type: Article

References (32)

1. Hagist C, Kotlikoff LJ. Who's Going Broke? Comparing Growth in Health care Costs in Ten OECD Countries, NBER Working Papers, No. 11833, December 2005
2. Cox P, ed. Financing Sustainable Healthcare In Europe: New Approaches For New Outcomes, February 2007. Available at: http://www.sustainhealthcare.org/ navigation/The-Cox-Report.pdf. Accessed December 12, 2008
3. The Conference Board of Canada. Challenging Health Care System Sustainability: Understanding Health System Performance of Leading Countries. March 2004. Available at: http://www.conferenceboard.ca.
4. International Trade Administration. Pharmaceutical Price Controls in OECD Countries Implications for U.S. Consumers, Pricing, Research and Development, and Innovation. Washington, DC: US Department of Commerce, December 2004
5. Tyrer JH, Eadie MJ, Sutherland JM, et al. Outbreak of anticonvulsant intoxication in an Australian city. BMJ 1970;4:271-3
6. Dahl M, Wolf P. Comparative daily profiles of lamotrigine. Poster #3.019 presented at the 1 st Annual North American Regional Epilepsy Congress of the American Epilepsy Society, December 2006, San Diego, CA
7. Cremieux PY, Ouellette P, Petit P. Do drugs reduce utilization of other healthcare resources? Pharmacoeconomics. 2007; 25:209-21
8. LeLorier J, Duh MS, Paradis PE, et al. Economic impact of generic substitution of lamotrigine: projected costs in the United States using findings in a Canadian setting. Curr Med Res Opin 2008;24:1069-81
9. Andermann F, Duh MS, Gosselin A, et al. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007;48:464-9
10. Labiner DM, Duh MS, Paradis PE, et al. Impact of generic substitution of antiepileptic drugs on medical resource utilization in the United States. Poster presented at the 62 nd Annual Meeting of American Epilepsy Society, Seattle, WA, December 5-9, 2008
11. Volger S, Habl C, Leopold C, et al. PPRI Report. Commissioned by European Commission, Directorate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth, June 2008. Available at: http://ppri.oebig.at/Downloads/Publications/PPRI-Report-final.pdf. Accessed on January 16, 2009
12. Crawford P, Feely M, Guberman A, et al. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006;15:165-76
13. Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 2004;5:995-8
14. Haskins L, Tomaszewki KJ, Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav 1998;11:98-105
15. Caves RE, Whinston MD, Hurwitz MA. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers: Microeconomics. Washington, DC: Brookings Institution, 1991, 48p
16. Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997;54:752-73
17. Association Québécoise des É tablissements de Santé et de Services Sociaux (AQESSS), Système intégré d'analyse de la performance (SIAP). Montréal, Québec: AQESSS, 2004-5
18. Statistics Canada, CANSIM Table 320-0020, series v41691872 and v41691869
19. Mooney CZ, Duval RD. Bootstrapping: a nonparametric approach to statistical inference. Newbury Park, CA: Sage Publications, 1993
20. Organization for Economic Co-operation and Development (OECD), OECD Health Data 2008, June 8 th edition. Available at: http://www.oecd.org.
21. IMS Health, units and sales. France, Germany, Italy and United Kingdom. Risperidone, gabapentin, lamotrigine, and oxcarbazepine. January 2001 to July 2008. Available at: http://www. imshealth.com.
22. Kaiser Family Foundation. Prescriptions drug trends, Fact Sheets #3057-03 to 3057-07, November 2005, June 2006, and May 2007. Available at: http://www.kff.org. Accessed August 7, 2008
23. Bank of Canada. Monthly and Annual Noon Exchange Rates Averages, Average of 251 days, 2007. http://www.bankbanque-canada.ca/en/rates/exchange-avg-pdf. html. Accessed August 8, 2008
24. Eurostat. ECU/EUR exchange rates versus national currencies, 2007 http://epp.eurostat.ec.europa.eu. Accessed August 8, 2008
25. LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008;70:2179-86
26. Grootendorst, P. Do drugs matter? Effect of drug plan eligibility on drug use among the elderly, social assistance recipient and the general population. Hamilton, Ontario: Research Institute for Quantitative Studyies in Economics and Population (QSEP), 2000:77p
27. Blachier C, Kanavos P. Pharmaceutical Pricing and Reimbursement. Available at http://ec.europa.eu/enterprise/ phabiocom/docs/tse/france.pdf
28. Brandt N. Moving towards more sustainable healthcare financing in Germany. OECD Economics Department, Working Paper No. 612, 2008
29. Garattini L, Ghislandi S. Off-patent drugs in Italy. A shortsighted view? Eur J Health Econ 2006;7:79-83
30. Nguyen-Kim L, Or Z, Paris V, et al. The politics of drug reimbursement in England, France and Germany. Health Econ Letter. No. 99, October 2005
31. Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996;23:139-48
32. Grimes DA, Schultz KF. Bias and causal associations in observational research. Lancet 2002;359:248-52